Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Healthcare Biotechnology

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > Price Action

<< Previous

Bullboard Posts

Next >>

Comment by GoldenArmon Oct 21, 2021 4:33pm

95 Views

Post# 34034655

RE:RE:RE:Price Action

Yes you are correct. I've been in a lot of stocks like this one and with the low volume buys and sells you get these kind of price actions. So basically saying I'm not going to panic over it. I'm hoping for some material news to come out soon. I would be interested to know if insiders are buying because if they are we'll see more action to the upside if they are. IMHO.

<< Previous

Bullboard Posts

Next >>

3 Mid-Sized Stocks to Consider This Season